For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- 37 Pharma Execs Get 100 Million-Plus Yen in FY2021, Top 3 at Takeda: Securities Reports
July 1, 2022
- Despite 4 Trillion Yen Debt, Takeda CEO Confident in Deleveraging, Pipeline Boost, Shareholder Returns
June 30, 2022
- Pfizer Seeks Japan Approval of Aplastic Anemia Med
June 30, 2022
- Tissue-Engineering Market in Asia to Hit 712 Billion Yen in 2030: Fuji Keizai
June 30, 2022
- Takeda CEO’s Pay Down to 1.86 Billion Yen in FY2021
June 30, 2022
- Wholesalers Bear Over 50 Billion Yen in Annual Costs Tied to Restricted Drug Supply: Crecon Estimate
June 29, 2022
- Astellas/Sutro to Codevelop Next-Gen Immunostimulatory ADCs for Cold Tumors
June 29, 2022
- Solasia, Nippon Kayaku Forge Capital and Business Tie-Up
June 29, 2022
- Ono Expands CAR-T Collaboration with Fate Therapeutics
June 29, 2022
- Shingrix Filed in Japan for At-Risk Adults aged 18 and Older: GSK
June 29, 2022
- Brexpiprazole Cuts Alzheimer’s Agitation in PIII Study: Otsuka/Lundbeck
June 28, 2022
- Astellas’ Pompe Gene Therapy Trial Hit with FDA Clinical Hold
June 28, 2022
- Enhertu Filed for HER2 Low Breast Cancer in Japan: Daiichi Sankyo
June 28, 2022
- Novo Japan Seeks Thumbs-Up for Sogroya Use in Short Stature
June 28, 2022
- Mitsubishi Tanabe, EditForce Join Forces for Discovery of Gene Therapy in CNS
June 28, 2022
- Kyowa Kirin Gets EU Backing for Crysvita’s Label Expansion into TIO
June 28, 2022
- Kobayashi Kako to Withdraw Marketing License Next April
June 28, 2022
- Daiichi Sankyo CEO Snags 341 Million Yen in FY2021: Securities Filing
June 28, 2022
- Bimzelx as Driver, UCB Set to Derive Half of Global Sales from Immunology Biz
June 28, 2022
- Ex-Wakamoto Chairman Misused 1.7 Million Yen from Company’s Coffers
June 27, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…